Introduction
Cutaneous T-cell lymphomas (CTCL) are a group of lymphoproliferative disorders that are characterized by localization of malignant T lymphocytes in the skin, mainly in the epidermis. The classical forms of CTCL are plaque-type mycosis fungoides (MF) and Sezary syndrome (SS). SS is a rare, leukemic variant of CTCL that typically presents with erythroderma, peripheral lymphadenopathy, severe pruritus and malignant, circulating T lymphocytes, the Sezary cells.
While MF usually is a slowly progressive disease, SS runs a more aggressive course with a high mortality rate and a median survival time of 2-4 years. The probability of survival in CTCL can be accurately predicted by a formula based on the clinical CTCLseverity index (CTCL-SI) 1 that evaluates the involvement of the skin, lymph nodes, blood and visceral organs. 2 
Sezary cells are malignant circulating CD4
þ T cells that derive from the same T-cell clone as the malignant T cells in skin and other organs as demonstrated by T-cell receptor (TCR) gene rearrangement analysis studies. 3, 4 The detection of Sezary cells in the peripheral blood is primarily based on morphological features such as cerebriform nuclei; therefore, 'Sezary cells' may be detected in healthy individuals as well as in inflammatory dermatoses. As a consequence, an arbitrary threshold has been set at 5% (20%) Sezary cells among peripheral blood mononuclear cells (peripheral blood lymphocytes) for the diagnosis of SS in the blood. Loss of CD26 or CD7, expression of CD158k/ KIR3DL2, analysis of Her2 neu gene copy number, and lack of T regulatory cells may be informative, 5, 6 but only apply to a subpopulation of SS patients. Recently, multi-gene qRT-PCR was proposed to improve the molecular diagnosis of SS cells in the peripheral blood, but the method still awaits confirmation by other groups and validation using independent patient samples. 7 In SS and MF, chemotherapy does not improve survival, but impairs quality of life; due to frequent recurrences, allogeneic bone marrow transplantation is no successful treatment option either. Stage-adapted therapy as pursued currently by most groups aims at mitigating the course of the disease, but a potentially curative treatment regimen for SS or MF does not exist, indicating the urgent necessity to identify novel therapeutic targets.
We here performed Affymetrix microarray-based gene expression profiling of SS peripheral blood mononuclear cells (PBMC) versus healthy controls followed by qRT-PCR and statistical analysis to identify and validate candidate genes as novel diagnostic markers and putative therapeutic targets for the disease. We also assessed the predictive capacity of SSassociated genes identified by others.
Patients, materials and methods

Patients
A total of 41 CTCL patients were included in the study, 27 patients with SS (14 male and 13 female), median age 68 years, ranging from 48 to 83 years, stage III/IVA and 14 patients with MF (10 male and 4 female), median age 59 years, ranging from 16 to 95 years, stage IB-IVA. The patients were diagnosed according to the WHO-EORTC classification of cutaneous lymphomas and the criteria of the International Society of Cutaneous Lymphomas. The extent of CTCL involvement was quantified by the CTCL-SI. 2 Analysis of the TCR g or b chain genes was performed using the well-established polymerase chain reaction-based GeneScan technique. 3 All patients with SS had erythroderma, peripheral lymphadenopathies, a highly elevated CD4/CD8 ratio and atypical circulating Sezary cells in the blood (Supplementary Table 1 ). For comparative analysis, blood samples were obtained from 10 healthy donors (4 males and 6 females, median age 57 years, ranging from 34 to 84 years). In addition for qRT-PCR experiments, peripheral blood samples and lesional skin biopsy specimens of 24 patients with different inflammatory skin diseases (ID) such as psoriasis (16 patients, 13 male and 3 female, median age 53 years, ranging from 28 to 76 years), atopic dermatitis (6 patients, 5 male and 1 female, median age 46 years, ranging from 24 to 78 years) and erysipelas (2 patients, 1 male and 1 female of 28 and 78 years of age) were obtained. Furthermore 15 additional samples of healthy donors (5 male and 10 female, median age 48 years, ranging from 25 to 89 years) and peripheral blood T cells activated for 3 days with phytohemagglutinin were also included in the study ( 
Preparation of PBMCs, RNA isolation and cDNA synthesis
Peripheral blood mononuclear cells (PBMCs) were isolated from Sezary patients and control individuals using the Ficoll gradient centrifugation. CD4 þ T cells were selected from PBMC using CD4 þ -Isolation Kit I and CD4 þ -Isolation Kit II for cell culture according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). For additional purging of CD4 þ T cells from residual monocytes and dendritic cells, monocytes and dendritic cells were depleted using magnetic labeling with reagents provided in Blood Dendritic Cell Isolation Kit II (Miltenyi Biotec). Using this procedure, 495% of residual monocytes and dendritic cells were removed as confirmed by FACS analysis. RNA was isolated from whole PBMCs and CD4 þ T cells using RNeasy Mini or Midi Kit and from tissue sections using RNeasy Mini fibrous tissue Kit according to the manufacturer's instructions (QIAGEN, Hilden, Germany). For cDNA synthesis, total RNA (2 mg) was treated with 2 U Turbo DNase (Ambion, Austin, TX, USA) and used for Reverse Transcription (RT) with Superscript II reverse transcriptase (Invitrogen, Karlsruhe, Germany) using oligo dT primers according to the recommendations of the manufacturer. The obtained cDNA was diluted 1:10 with ddH2O and 1 ml was used for each PCR reaction.
Microarray processing
Microarray hybridization, scanning and analysis was performed by Zentrum fü r Medizinische Forschung (Medical Research Center (ZMF), University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany). Twenty Human Genome U133 Plus 2.0 Arrays from Affymetrix (ten control samples and ten samples from SS patients) were utilized. Raw data from Affymetrix CEL files were analyzed using SAS software package Microarray Solution version 1.3 (SAS Institute, Cary NC). Gene annotation was obtained through the Affymetrix NetAffx website (http://www.affymetrix.com/analysis/index.affx). The quality control, normalisation and statistical modeling were performed by array group correlation, mixed model normalisation and mixed model analysis, respectively. Analysis of differential gene expression was based on a loglinear mixed model of perfect matches, 8 where group (SS or control) were considered to be with constant effects and the chip ID with random effect.
Real-time RT-PCR analysis
RT-PCR analysis was used to determine lack of gene expression of candidate genes in CD4 þ T cells of healthy donors and ID versus SS patients. Primers used were from Metabion (Martinsried, Germany); primer sequences and the standard RT-PCR procedures applied will be supplied by the authors upon request. Real-time PCR analysis was performed using TaqMan PCR master mix (Applied Biosystems, Darmstadt, Germany) together with TaqMan probes and primers (MWG-Biotech, Martinsried, Germany) using standard conditions. Each primer and probe concentration was optimized before use. The sequences and concentrations used for quantification of the selected genes are listed in the Supplementary Table 2 . Human GAPD was used as an internal control. The experiments were performed on ABI PRISM 7000 sequence detection system (Applied Biosystems). The expression levels of analyzed genes were normalized to GAPD mRNA expression. Each assay included a negative control (no template DNA) and all were carried out in quadruplicate (96-well maximum). Relative quantification of the gene expression was performed using relative quantification module of 7000 system software version 1.2.3. As a calibrator (expression value taken as 1), one of the cell lines or SS2 sample was taken depending on the level of expression (Supplementary Table 2 ).
Immunuhistochemistry
An anti-human CDO1 antiserum was raised in rabbits against synthetic peptide representing the amino acids 52-69 (gb AAB58352) using a standard immunization protocol (PSL GmbH, Heidelberg, Germany). Pre-immune serum was used as a negative control. cryosections of liver tissue (5 mm) and cytospins of CD4 þ T cells were fixed with acetone and airdried. For immunohistochemical analysis, the CDO1 antiserum was used at a dilution of 1:250; HRP-conjugated-anti-rabbit IgG (Santa Cruz Biotechnology, Heidelberg, Germany) was used as a secondary antibody at a dilution of 1:200. Detection was performed using AEC substrate (Dako, Hamburg, Germany).
Statistical analysis of real-time RT-PCR data
The comparison of gene expression between the groups was performed by using the Wilcoxon-Mann-Whitney U-test (for two samples) or the Kruskal-Wallis test (for more than two samples). The test result was considered significant when P-value was less than 0.05. In order to determine overexpression of which genes is specifically related to SS, we further analyzed the quantitative real-time PCR data for SS patients, patients with ID and control samples using the receiver operating characteristic (ROC) methodology based on logistic regression. Logistic regression analysis is a statistical method for analyzing dichotomous response while accommodating adjustments for one or more explanatory variables. 9 Wald's test has been used in order to assess if the explanatory variables have a significant influence on the dichotomous response variable. 10 Using this approach and depending on a chosen cut-off point, it is possible to assess the specific values for sensitivity and for specificity of gene expression, related to a special cut-off value. Usually, when sensitivity and specificity are regarded as equally important, the optimal cut off is the one in which the sum of sensitivity and specificity is maximal. Therefore, in Table 1b the values for sensitivity and specificity are given for the optimal cut off. Plotting both quality measures for all possible cut-off points simultaneously into a graph (sensitivity on the x axis versus 1Fspecificity on the y axis) creates the ROC curve (receiver operator statistics). The area under the ROC curve (AUCFarea under the curve) is a measure of the quality of the model, that is, a measure of association of predicted probabilities and observed responses. The nearer the AUC value is close to 1, the better is the diagnostic procedure. Values of about 0.5 symbolize that this procedure is only as good as random assignments. Hence, AUC is suitable to compare several diagnostic tests. In addition, a multivariable analysis including several genes was also performed. All statistical calculations were performed using SAS (release 8.02; SAS institute Inc., Cary, NC, USA). 9 
Results
Differential gene expression in leukemic CTCL cells in SS
In order to identify genes differentially expressed in leukemic cells of SS patients, total RNA was isolated from the PBMC of 10 SS patients (Supplementary Table 1 , No. 1-10) and 10 healthy blood donors (HBD), labeled and hybridized onto Affymetrix HG-U133 Plus 2.0 Genchip. Significant alterations in gene expression were found at a log 10 P-value 46.04 (Bonferroni correction) in 294 probe sets. Among these 294 probe sets, the expression of only 16 genes was increased at least twofold excluding several genes reported previously to be associated with SS such as PLS3 and KIR3DL2. 6, 11, 12 To include a broader range of genes for further investigation, Po0.02 was then set as the threshold. Using this setting, we found the expression of 53 candidate genes to be increased at least twofold (Supplementary Table 3 ).
Real-time RT-PCR confirmation of candidate genes in CD4 þ T cells (Table 1a) . Further statistical evaluation of the quantitative data was done using ROC methodology based on logistic regression. Good discrimination capacity was seen for all 10 genes analyzed (Table 1b) . Out of these 10 genes, 5 showed an AUC value (maximum 1) above 0.9 and among these genes, 2 (DNM3 and CDO1) showed a specificity of 100% (Table 1b) . To exclude any contribution of CD4 þ monocytes and dendritic cells to the results of the analyses of CD4 þ T cells, additional purging procedures using magnetic cell sorting for definitive depletion of monocytes and dendritic cells were performed. Real-time PCR analysis revealed similar or even higher gene expression of the candidate genes in highly purified SS CD4 þ T cells (data not shown). We also analyzed the expression of factors involved in the biochemical pathway of taurine and glutathione biosynthesis including CSAD (cysteine sulfinic acid decarboxylase), SLC6A6 (taurine transporter) and GCLM (gamma Glutamylcysteine Synthetase) (Supplementary Table 2 ); these genes were expressed, but not upregulated (data not shown).
Real-time RT-PCR confirmation of candidate genes in PBMC
Since PBMC samples are easier to obtain from patients and easier to process for routine analysis than CD4 þ T cells, we analyzed the expression of the 10 candidate genes also in PBMC samples from patients and controls, although PBMC contain clearly more cellular contaminants beyond the tumor cells (Sezary cells) than CD4 þ T-cell isolates. PBMC samples were obtained form 17 additional cases of SS patients (Supplementary Table 1 , No. 11-27), 10 healthy blood donors (different from those used for microarray analysis), and 10 patients with inflammatory diseases (4 psoriasis, 4 atopic dermatitis and 2 erysipelas). Relative quantification of gene expression revealed that the observed increase of gene expression in SS PBMCs in comparison to HBD was statistically significant for all genes with the exception of IGFBP4 (Table 2a ). In the case of comparison of SS PBMC with ID samples, a significant increase in expression was observed for 7 genes excluding RDH10, DUSP4 and IGFBP4 (Table 2a) . Further statistical evaluation of the quantitative data was again done using ROC methodology based on logistic regression. In the PBMC samples, CDO1 and DNM3 showed the highest AUC values of 0.896 and 0.884, respectively (Table 2b ). The lowest discrimination rates were seen in PBMC for the genes RDH10, IGFBP4 and DUSP4, which was in accordance with the results of the Wilcoxon-Mann-Whitney U-test (Table 2a) .
Since none of the genes analyzed provided 100% sensitivity in combination with 100% specificity, we next tested whether multiple analyses of expression values of several genes had a predictive capacity better than that of single genes. A multiple logistic regression model including several genes was performed using FORWARD-selection in SAS Procedure PROC LOGISTIC in order to find the ideal combination of genes and to optimize the discrimination between SS patients and controls. The combined analysis of CDO1 and DNM3 gene expression levels in PBMC samples had the best predictive value (AUC ¼ 0.956) for the discrimination between SS patients and control samples. In contrast, analysis of CD4 þ T-cell samples revealed that combined analysis of two or more genes did not result in an improved predictive capacity compared to analysis of any single gene alone. These results indicate that the combined analysis of the expression of CDO1 and DNM3 in PBMC samples may suffice for the differential diagnosis of SS versus ID and is an alternative to the analysis of single gene expression in CD4 þ T-cell samples.
Comparison of CDO1/DNM3 expression with the 5 gene qRT-PCR assay proposed by Nebozhyn et al. 7 Recently, Nebozhyn et al. 7 proposed a qRT-PCR assay analyzing STAT4 (kk), CD1D (m), PLS3 (mm), TRAIL (m) and GATA-3 (m) in PBMC as a highly reliable test for the diagnosis of SS. Real-time PCR analysis of these five genes in our patient samples as compared to HBD or ID confirmed the strong reduction in expression of STAT4 and the strong overexpression of PLS3 in SS while expression of TRAIL and GATA-3 was not significantly altered in contrast to the results of Nebozhyn et al. 7 Also in strong contrast to Nebozhyn et al., CD1D was even significantly downregulated in our SS patient samples (Table 2a) . Statistical evaluation using ROC methodology based on logistic regression showed an excellent discriminative capacity for STAT4 (AUC ¼ 0.906) and a medium value for CD1D (AUC ¼ 0.796) (Table 2b ). When analyzing expression of our 10 genes and the genes of Nebozhyn et al. 7 using the multiple logistic regression model on data generated in our patient and control samples, the combination of DNM3 and STAT4 (AUC ¼ 0.957) and the combination of DNM3 and CDO1 (AUC ¼ 0.956) had the best predictive values for the discrimination between SS patients and control samples.
Analysis of the expression of CDO1 and DNM3 in tissue samples of SS and MF patients and in activated T cells
As a CTCL, MF is related to, but different from SS. A major difference between the two diseases is both the negligible tumor load as assessed by TCR gene rearrangement analyses and the lack of Sezary cells identified morphologically in the peripheral blood of MF patients. We therefore predicted that the marker molecules of the Sezary cells identified here would rather not be expressed in PBMC and skin samples of MF patients. Out of the 10 selected genes, the best predictive markers, that is, CDO1 and DNM3, were also tested in PBMC and skin biopsy samples from MF patients. qRT-PCR was used to analyze PBMC samples from MF patients (n ¼ 10) and the results were compared with the results from the 27 SS patients and the 10 inflammatory skin disease patients (see above). For PBMC samples, threshold values were set using the results from the ROC analyses. The expression of CDO1 (Figure 1a ) and DNM3 (Figure 1b ) was only increased in 1 out of 10 MF PBMC samples similar to control samples from HBD and ID while the percentage of positive SS samples was 74 and 78%, respectively. qRT-PCR was also used to analyze skin samples from SS patients (n ¼ 10; Supplementary Table 1), MF patients (n ¼ 10) and ID patients (psoriasis, n ¼ 5). Since the number of skin samples was not large enough to calculate threshold values, expression values higher than the highest expression value in the control group (ID) were considered positive. The expression of CDO1 (DNM3) was detected to be increased in 6 (5) out of 10 SS patients (Figures 1c  and d) , while expression of the two genes was not increased among the 10 MF skin samples. These data indicate that CDO1 and DNM3 are specifically upregulated in SS, as there was no difference between MF and ID. A higher number of skin samples, however, are needed to confirm this finding. In addition, CDO1 expression was analyzed in activated T cells of healthy donors. However, T-cell activation did not exert any effects on CDO1 expression indicating that expression of CDO1 is an event associated with the molecular pathogenesis of SS (Supplementary Text 1) .
Immunohistochemical analyses of CDO1 in PBMC
Immunohistochemical staining was performed with rabbit antihuman CDO1 antiserum on samples of CD4 þ cells isolated from SS patients and healthy donors. Staining of hepatocytes in liver samples served as a positive control. Strong staining of about 30% of CD4 þ T cells was observed in the case of SS patients while only few CD4 þ T cells of healthy donors showed positive staining which was, however, much weaker than that of SS CD4
þ cells (Supplementary Figure 1) .
Discussion
In the present study, we used global gene transcription analysis with Affymetrix Gene Chip technology to identify genes characteristic for leukemic CTCL cells in SS patients. Special interest was directed to genes that are highly informative as single genes or in combination for diagnostic purposes as determined by qRT-PCR. Seven genes (PLS3, DNM3, IGFL2, CDO1, TNFSF11, NEDD4L, KLHDC5) were found to be significantly overexpressed in SS. While DNM3, IGFL2, CDO1, NEDD4L and KLHDC5 are described to be overexpressed in Sezary cells for the first time in this study, PLS3 and TNFSF11 have previously been noted to be highly expressed in Sezary cells. [11] [12] [13] While single gene analysis with any of these seven genes may suffice in CD4 þ T-cell samples, high sensitivity and high specificity in PBMC samples is achieved preferentially by combined analysis of mRNA expression levels of CDO1 and DNM3. Analysis of CDO1 and DNM3 in PBMC and skin samples of SS versus MF patients also indicated that these markers identify SS as a molecularly unique CTCL.
The three microarray studies previously performed in SS have not yielded uniform and reproducible molecular signatures for the disease. 11, 13, 14 This is probably due to the differences in microarray platforms used by the different groups, 11, 13 to strategic differences in identifying common versus differential traits of SS and MF, 11, 13, 14 and to selection of control populations including Th2 T cells. 13 Despite the differences between previous gene profiling studies in SS, our microarray analysis partially confirmed the results of those two studies comparing SS PBMCs/CD4 þ T cells with normal donors. 13, 14 Since the analysis of whole gene expression profiles is an expensive and complicated method, the markers identified by microarray experiments are usually used for the design of real-time PCR-based test systems. In this respect, the selection of the statistical model used for evaluating the data obtained by real-time PCR may considerably influence the outcome of the analysis. To evaluate our data and to identify useful diagnostic marker genes, we used ROC methodology based on logistic regression, a statistical approach that is more robust than linear discriminant analysis used by others. 7, 11 As a result, we show here that combined analysis of the expression of CDO1 and DNM3 in PBMCs achieves high specificity and sensitivity in the diagnosis of SS. When we compared our results with the multigene qRT-PCR assay analyzing expression of STAT4, PLS3, TRAIL, GATA-3 and CD1D as proposed by Nebozhyn et al., 7 it turned out that only STAT4 (and PLS3) had a similarly high discriminative power for the diagnosis of SS as DNM3 and CDO1 and that STAT4 analysis may complement DNM3 analysis as effectively as analysis of CDO1 in a combined approach. We therefore suggest that a multi-center trial should evaluate a 4 gene qRT-PCR assay consisting of three upregulated genes (PLS3, DNM3, CDO1) and one downregulated gene (STAT4) to minimize misclassifications in the diagnosis of SS.
The SS gene signature identified here does not only provide new SS marker molecules that can be used for diagnostic purposes, but it also opens novel clues to unravel the molecular pathogenesis of SS. One of the most consistent SS marker genes newly identified here, that is, cysteine dioxygenase (CDO1), is the rate limiting enzyme in the synthesis of taurine, an important semi-essential amino acid. The key role of CDO1 in this biosynthetic pathway is underlined by the finding that the other components of this biosynthetic pathway such as CSAD, SLC6A6 and GCLM (Supplementary Table 2 ) were expressed, but not upregulated in SS PBMC (data not shown). Taurine itself is highly protective against apoptosis of T cells induced by CD95 engagement or by AICD 15 and inhibits apoptosome formation. 16 Taurine is also chemoprotective against methotrexate and vincristine. 17 In case of vincristine, taurine inhibits the degradation of vincristine by hypochloric acid (HOCl), a process in which taurine chloramine is generated. It is important to note that impaired apoptosis is a hallmark of CTCL. CDO1 is not normally expressed in peripheral blood leukocytes, but it is highly expressed in liver and brain. We have shown here that CDO1 is not induced in CD4 þ T cells by either activation with PHA, IL-2, anti-CD2, anti-CD3 or a combination of anti-CD3 and anti-CD28. The CDO1 promoter, however, has been shown to harbor a c-myb-responsive element (gttg) at À71. 18 Interestingly, we have previously reported that c-myb is consistently overexpressed in PBMC from SS patients, but not PBMC from MF patients. 19 Upregulated c-myb may well contribute to upregulation of CDO1 in SS PBMC indicating hierarchical pathways in the molecular pathogenesis of SS.
The importance of transcription factor-mediated regulation of gene expression in SS is further substantiated by the following findings: (a) TWIST1, a bHLH transcription factor known to be overexpressed in SS and also found upregulated by gene profiling in SS in this study (log 10 P46.2), regulates DNM3 expression; 20 (b) PEG-10 found upregulated by gene profiling in SS in this study (log 10 P43.1) is a target gene of c-myc, another oncogene and transcription factor involved in the pathogenesis of SS 21 and (c) the PLS3/T-plastin promoter is not methylated in lymphocytes despite strong methylation in other leukocytes 22 rendering it accessible to SS-associated transcriptional regulators still to be identified. One such putative transcriptional regulator could be TOX, another bHLH transcription factor found upregulated by gene profiling in SS in this study (log 10 P46.3) that is known to be involved in thymocyte differentiation. 23 In summary, we have identified and validated marker genes differentially expressed by leukemic T cells in SS, including PLS3, DNM3, IGFL2, CDO1, TNFSF11, NEDD4L and KLHDC5. These genes well discriminate between peripheral blood mononuclear cells in SS as compared to healthy controls and ID. In addition, CDO1 and DNM3 distinguish between PBMCs 
